«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:

期数:

2024年01期

页码:

63-67

栏目:

论著

出版日期:

2024-02-20

文章信息/Info

Title:

Effects of vitamin D₃ combined with Montelukast sodium on serum VEGF, TGF-β1 and lung function in patients with bronchial asthma

作者:

暴 静¹; 2; 吴 霞¹; 2; 田雅萍¹; 2; 尹 钢³

161000 齐齐哈尔,齐齐哈尔市第一医院呼吸内科¹、行风办³161005 齐齐哈尔,齐齐哈尔市公安医院呼吸内科²

Author(s):

Bao Jing¹; 2;  Wu Xia¹; 2;  Tian Yaping¹; 2;  Yin Gang³.

¹ Department of Respiratory Medicine; ²Department of Respiratory Medicine, Public Security Hospital of Qiqihaer, Qiqihaer 161005, China; ³Morals Office, the First Hospital of Qiqihaer, Qiqihaer 161000, China

关键词:

支气管哮喘;  维生素D₃;  孟鲁司特钠;  肺功能;  血管内皮生长因子;  转化生长因子

Keywords:

Bronchial asthma;  Vitamin D₃;  Montelukast sodium;  Lung function;  Vascular endothelial growth factor;  Transforming growth factor

分类号:

R562

DOI:

10.3877/cma.j.issn.1674-6902.2024.01.012

摘要:

目的 分析维生素D₃联合孟鲁司特钠治疗支气管哮喘对血管内皮生长因子(vascular endothelial growth factor, VEGF)和转化生长因子(transforming growth factor, TGF-β1)及肺功能的影响。方法 选取我院在2020年1月至2022年12月收治的69例支气管哮喘患者为对象,维生素D₃联合孟鲁司特钠治疗32例为观察组,孟鲁司特钠治疗37例为对照组。比较两组患者的治疗效果、临床症状、肺功能参数、免疫功能水平、血清VEGF和TGF-β1水平和不良反应情况。结果 观察组治疗后有效28例(87.50%),对照组有效25例(67.56%)(P<0.05); 两组临床症状得到缓解,观察组喘息缓解(3.45±0.55)d、咳嗽缓解(5.87±1.32)d、胸闷缓解(4.55±1.07)d、呼吸困难缓解(1.38±0.25)d和哮鸣音缓解(4.44±1.32)d低于对照组(P<0.05); 两组FVC、FEV₁、PEF水平较治疗前上升,观察组FVC(4.56±1.23)L、FEV₁(2.98±0.53)L、PEF(3.97±1.98)L/min高于对照组(P<0.05); 两组免疫功能水平较治疗前改善(P<0.05),观察组CD3⁺(69.75±4.87)%、CD4⁺(45.13±3.56)%、CD4⁺/CD8⁺(1.78±0.56)高于对照组,CD8⁺(25.32±2.58)%低于对照组(P<0.05); 两组VEGF和TGF-β1水平较治疗前下降,观察组VEGF(223.62±63.35)ng/L和TGF-β1(364±66.65)ng/L水平低于对照组(P<0.05)。结论 维生素D₃联合孟鲁司特钠治疗支气管哮喘有效,能够缩短支气管哮喘患者临床症状,改善患者肺功能,提高免疫力,降低VEGF和TGF-β1水平具有意义。

Abstract:

Objective To analyze the effects of vitamin D₃ combined with Montelukast sodium on vascular endothelial growth factor(VEGF)and transforming growth factor(TGF-β1)and lung function in the treatment of bronchial asthma. Methods A total of 69 patients with bronchial asthma admitted to our hospital from January 2020 to December 2022 were selected as subjects. Vitamin D₃ combined with Montelukast sodium treated 32 cases as observation group, Montelukast sodium treated 37 cases as control group. The therapeutic effect, clinical symptoms, lung function parameters, immune function level, serum VEGF and TGF-β1 levels and adverse reactions were compared between the two groups. Results After treatment, 28 cases(87.50%)were effective in observation group and 25 cases(67.56%)in control group(P<0.05). The clinical symptoms of the two groups were relieved, the relief of wheezing(3.45±0.55)d, cough(5.87±1.32)d, chest tightness(4.55±1.07)d, dyspnea(1.38±0.25)d and wheezing(4.44±1.32)d in the observation group were lower than those in the control group(P<0.05). The levels of FVC, FEV₁ and PEF in the two groups were higher than those before treatment, and FVC(4.56±1.23)L, FEV₁(2.98±0.53)L and PEF(3.97±1.98)L/min in the observation group were higher than those in the control group(P<0.05). The level of immune function in both groups was improved compared with that before treatment(P<0.05). CD3⁺(69.75±4.87)%, CD4⁺(45.13±3.56)% and CD4⁺/CD8⁺(1.78±0.56)in observation group were higher than those in control group, and CD8⁺(25.32±2.58)% were lower than those in control group(P<0.05). The levels of VEGF and TGF-β1 in the two groups were lower than those before treatment, and the levels of VEGF(223.62±63.35)ng/L and TGF-β1(364±66.65)ng/L in the observation group were lower than those in the control group(P<0.05). Conclusion Vitamin D₃ combined with Montelukast sodium is effective in the treatment of bronchial asthma, which can shorten the clinical symptoms of patients with bronchial asthma, improve lung function, enhance immunity, and reduce the levels of VEGF and TGF-β1.

参考文献/References:

1 娄月妍, 郑 宇, 张丽妍, 等. 呼出气一氧化氮在哮喘中的临床意义[J/CD]. 中华肺部疾病杂志(电子版), 2020, 13(3): 297-301.
2 陈婉丽, 魏文娟. 支气管哮喘健康教育路径表临床应用效果观察[J]. 山西医药杂志, 2019, 48(13): 1618-1619.
3 介雪妍, 蒋 萍. 生物靶向制剂治疗哮喘的研究进展[J]. 中华医学杂志, 2019, 99(20): 1597-1600.
4 Palumbo ML, Prochnik A, Wald MR, et al. Chronic Stress and Glucocorticoid Receptor Resistance in Asthma[J]. Clin Ther, 2020, 42(6): 993-1006.
5 张 勇, 韩兆勇. 孟鲁司特钠片联合沙美特罗替卡松粉吸入剂治疗哮喘-慢性阻塞性肺疾病重叠综合征的临床研究[J]. 中国临床药理学杂志, 2020, 36(7): 744-746.
6 刘文君, 王亚亭, 毕良学, 等. 维生素D₃辅助治疗儿童重症哮喘可降低血清TLR4, S100β蛋白水平以及延缓哮喘复发[J]. 中国免疫学杂志, 2018, 34(9): 1382-1386.
7 中华医学会. 支气管哮喘基层诊疗指南(实践版·2018)[J]. 中华全科医师杂志, 2018, 17(10): 763-769.
8 唐文慧, 张 伟, 李春梅. 布地奈德福莫特罗联合孟鲁司特钠治疗支气管哮喘的疗效及对炎症因子水平的影响[J]. 医学综述, 2020, 26(12): 2493-2497.
9 Uryasev OM, Nikitina IN, Lazareva O, et al. Clinical course features of bronchial asthma combined with pathology of cardiovascular system[J]. Pakistan J Medical & Health Sciences, 2019, 13(1): 259-262.
10 费 凡, 吉宁飞, 黄 茂. 支气管哮喘发病机制的新认识[J]. 国际呼吸杂志, 2018, 38(12): 955-960.
11 刘汶睿, 高丽娜, 于书娴, 等. 支气管哮喘患者血清IL-27与IFN-γ及肺功能相关性分析[J/CD]. 中华肺部疾病杂志(电子版), 2023, 16(2): 224-226.
12 Kostiuk I, Kosyachenko KL, Kosacenko L. Specific features analysis of inhalation medication use to treat bronchial asthma in children[J]. World Science, 2019, 10(50): 51-56.
13 Yun Z, Wang D, Qu Y. Relationship between bronchial asthma and glucocorticoid receptor gene bcl-I single nucleotide polymorphism[J]. J Clin Case Dis, 2018, 5(3): 8-12.
14 Oh H, Stickley A, Singh F, et al. Asthma and Mental Health: Findings from the National Comorbidity Survey Replication[J]. Psychiatry Res, 2018, 12(46): 271.
15 黄书花, 张玉娇, 马 玮, 等. 老年慢性支气管哮喘急性发作影响因素[J]. 中国老年学杂志, 2022, 42(16): 4098-4101.
16 张华根, 曾伟坚, 彭贵霞, 等. 布地奈德福莫特罗粉吸入剂联合孟鲁司特钠在哮喘-慢阻肺重叠综合征患者治疗中的应用研究[J]. 实用药物与临床, 2018, 21(7): 811-814.
17 薛 满, 马春利, 尹春燕. 孟鲁司特钠联合氨溴索对支气管哮喘患儿血清sE-SLT和sICAM-1水平的影响[J]. 临床和实验医学杂志, 2019, 18(1): 68-71.
18 Andujar-Espinosa R, Salinero-González L, Illan-Gomez F, et al. Effect of vitamin D supplementation on asthma control in patients with vitamin D deficiency: the ACVID randomised clinical trial[J]. Thorax, 2021, 76(2): 126-133.
19 李 清, 黄成亮, 范贤明. 支气管哮喘-慢性阻塞性肺疾病重叠综合征患者血清维生素D与炎症因子及肺功能的相关性[J]. 广东医学, 2018, 39(4): 562-565.
20 Dodamani MH, Muthu V, Thakur R, et al. A randomized trial of vitamin D in acute-stage allergic bronchopulmonary aspergillosis complicating asthma[J]. Mycoses, 2018, 62(4): 180-186.
21 张志华, 肖晓晨, 梅少奇. 维生素D₃辅助治疗哮喘合并呼吸道感染对气道重塑及免疫功能影响[J/CD]. 中华肺部疾病杂志(电子版), 2022, 15(3): 355-357.
22 杨 帆, 刘 燕. 维生素D₃辅助治疗儿童咳嗽变异性哮喘临床疗效及对免疫功能的影响[J]. 临床肺科杂志, 2019, 24(9): 1656-1659.
23 岳圆圆, 韩 慧, 李忠梅. 孟鲁司特钠辅助治疗成人支气管哮喘的效果及对患者肺功能的影响[J]. 中国药物与临床, 2021, 21(17): 3013-3015.
24 杨 云, 焦德清, 周 利. 血清1, 25-(OH)2D₃和MMP-9对哮喘患儿病情发生发展的影响[J]. 中国现代医学杂志, 2018, 28(4): 86-90.
25 Lejeune S, Mordacq C, Drumez E, et al. Relationship between immune parameters during a severe exacerbation in allergic asthmatic children and asthma outcomes in the following year[J]. Clin Exp Allergy, 2020, 19(3): 406-411.
26 赖兰敏, 彭桉平, 陈曲波. 1, 25二羟维生素D₃的免疫调节及其在自身免疫性疾病中的研究进展[J]. 中国免疫学杂志, 2019, 35(17): 2169-2173.
27 Perelman JM, Pirogov AB, Prikhodko AG, et al. Bronchial inflammatory profile in interferon-gamma-mediated immune response in asthma patients during airway response to cold stimulus[J]. Frigid Zone Medicine, 2022, 2(4): 244-250.
28 周旭东, 邵 磊, 徐仁斌, 等. 孟鲁司特钠对支气管哮喘患者免疫指标及基质金属蛋白酶的影响[J]. 中国药物与临床, 2018, 18(12): 2184-2185.
29 Thongngarm T, Jameekornrak A, Chaiyaratana N, et al. Effect of gene polymorphisms in ADAM33, TGFβ1, VEGFA, and PLAUR on asthma in Thai population[J]. Asian Pac J Allergy Immunol, 2019, 40(1): 39-46.
30 Bhandari V, Choo-Wing R, Chapoval S, et al. Essential role of nitric oxide in VEGF-induced, asthma-like angiogenic, inflammatory, mucus, and physiologic responses in the lung[J]. Proc Natl Acad Sci U S A, 2018, 103(29): 11021-11026.
31 蒋凌志, 许丹媛, 杨志雄. 支气管哮喘患者血清25-(OH)D₃、TGF-β1水平与气道重塑的关系[J]. 山东医药, 2018, 58(12): 54-56.
32 Ozlem K, Mehmet YO, Bulent G, et al. Exhaled TGF-β1 levels before and after an exercise challenge in asthmatic and healthy children, and during exacerbation[J]. J Asthma, 2021, 58(3): 316-325.

备注/Memo

备注/Memo:

基金项目: 黑龙江省自然科学基金联合引导项目(LH2019H123)
齐齐哈尔市科技计划创新激励项目(CSFGG-2023357)
通信作者:暴 静, Email: mahuijie852@163.com

常用功能

更新日期/Last Update: 2024-02-20